$STRO News

News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts

Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results

Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

Wedbush Upgrades Sutro Biopharma to Outperform, Raises Price Target to $60

HC Wainwright & Co. Maintains Buy on Sutro Biopharma, Raises Price Target to $50

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

Sutro Biopharma Q1 EPS $(2.94) Beats $(3.77) Estimate, Sales $14.523M Beat $8.079M Estimate

Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program

Mizuho Initiates Coverage On Sutro Biopharma with Outperform Rating, Announces Price Target of $50

Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now

Sutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - Slideshow

Citizens Maintains Market Outperform on Sutro Biopharma, Raises Price Target to $41

Reported Sunday, Sutro Biopharma's STRO-004 Demonstrates Robust Antitumor Activity Across TF-Expressing Solid Tumor PDX Models With Improved Efficacy Versus Benchmark ADCs At AACR 2026

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

Citizens Maintains Market Outperform on Sutro Biopharma, Raises Price Target to $35

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma Enters Sales Agreement With TD Securities; Co. May Offer & Sell Shares Of Common Stock Of Up To $100M

Deutsche Bank Maintains Buy on Sutro Biopharma, Raises Price Target to $55

Sutro Biopharma shares are trading higher after multiple analyst firms raised their respective price targets on the stock.